Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Publication :
Associations between glucose tolerance, insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study

bul.description.provenanceeb bde spb autorité-manquante : Rankinenfr
bul.rights.dateAccepPubl2008-02-19fr
bul.rights.periodeEmbargoforeverfr
bul.rights.raisonEmbargoInfiniL’éditeur de Diabetic medicine n’autorise pas la diffusion en libre accès dans un dépôt institutionnel.fr
bul.rights.typeDatedatePublicationfr
dc.contributor.authorRuchat, Stéphanie-May
dc.contributor.authorLoos, Ruth
dc.contributor.authorBouchard, Claude
dc.contributor.authorRankinen, Tuomo
dc.contributor.authorPérusse, Louis
dc.contributor.authorWeisnagel, John
dc.contributor.authorVohl, Marie-Claude
dc.contributor.authorDesprés, Jean-Pierre
dc.date.accessioned2020-07-02T17:33:34Z
dc.date.available9999-12-31
dc.date.issued2008-02-19
dc.description.abstractAims:  Studies suggest that adiponectin (APM1) and its receptors 1 and 2 (AdipoR1 and AdipoR2) play an important role in the development of insulin resistance (IR). Our objective was to examine associations between APM1 (+45T>G, +276G>T and –3971A>G), AdipoR1 (−100G>T and −3882T>C) and AdipoR2 (−35361A>G and –1352G>A) genes single‐nucleotide polymorphisms (SNPs) and adiponectin plasma levels, indicators of glucose tolerance, insulin sensitivity (IS) and insulin secretion. Methods:  Six hundred and twenty‐two non‐diabetic subjects from the Quebec Family Study (QFS) underwent a 75‐g oral glucose tolerance test (OGTT), with measurement of fasting adiponectin, glucose, insulin and C‐peptide levels. Indices of glucose tolerance, IS and insulin secretion were derived from fasting and OGTT measurements. Results:  Significant evidence of association was found between indices of IS and APM1 and AdipoR1 SNPs. The APM1 –3971G/G homozygotes exhibited a reduced area under the curve of insulin during the OGTT (P = 0.007) and higher Cederholm index (P = 0.01) compared to the A/A homozygotes. The APM1 +45T>G variant was also associated with fasting (P = 0.002) and 2‐h (P = 0.007) glucose values as well as with higher Cederholm index (P = 0.04) and disposition index (P = 0.02). Finally, the AdipoR1 −3882T>C SNP was associated with fasting glucose (P = 0.03), the homeostasis model assessment for insulin resistance (P = 0.04) and an index of insulin secretion (P30/G30, P = 0.02). No evidence of association was found with plasma adiponectin levels. Conclusions:  These results provide evidence for an influence of common SNPs in the APM1 and AdipoR1 genes on different phenotypes of glucose and insulin metabolism associated with increased risk of type 2 diabetes.fr
dc.identifier.doi10.1111/j.1464-5491.2008.02396.xfr
dc.identifier.issn0742-3071fr
dc.identifier.pubmed18294218fr
dc.identifier.urihttp://hdl.handle.net/20.500.11794/39703
dc.languageengfr
dc.publisherWileyfr
dc.rightshttp://purl.org/coar/access_right/c_16ec
dc.subjectAdiponectinfr
dc.subjectAdiponectin receptorsfr
dc.subjectSingle-nucleotide polymorphismsfr
dc.subjectGlucose tolerancefr
dc.subjectInsulin sensitivityfr
dc.subjectInsulin secretionfr
dc.subject.rvmAdiponectinefr
dc.subject.rvmIntolérance au glucosefr
dc.subject.rvmPolymorphisme de nucléotide simplefr
dc.subject.rvmRécepteurs cellulairesfr
dc.subject.rvmInsulinefr
dc.titleAssociations between glucose tolerance, insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Studyfr
dc.typearticle de recherche
dc.type.legacyCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherchefr
dcterms.bibliographicCitationDiabetic medicine, Vol. 35 (4), 400-406 (2008)fr
dspace.accessstatus.time2024-03-23 18:04:01
dspace.entity.typePublication
relation.isAuthorOfPublication371c8953-e654-4a1b-af8e-0f527e339ea9
relation.isAuthorOfPublication4a555238-f5da-46cb-9ad8-d9f6cd5abe9c
relation.isAuthorOfPublication74032ee9-4680-45ce-98e8-4429b8aab916
relation.isAuthorOfPublicationc6556e24-9871-4032-b8ae-c952505b96b2
relation.isAuthorOfPublicationdf60781d-892a-41fb-9b41-91af85fc2cde
relation.isAuthorOfPublicatione5a2f6f5-0fb7-4917-b9cc-1ccab96fe68d
relation.isAuthorOfPublication.latestForDiscovery371c8953-e654-4a1b-af8e-0f527e339ea9
relation.isResourceTypeOfPublication4c433ef5-3937-4530-8252-cca17d715747
relation.isResourceTypeOfPublication.latestForDiscovery4c433ef5-3937-4530-8252-cca17d715747
rioxxterms.project.funder-nameGlaxoSmithKlinefr
rioxxterms.project.funder-nameSanofi Aventisfr
rioxxterms.versionVersion of Record (VoR)fr
rioxxterms.version-of-recordhttps://doi.org/10.1111/j.1464-5491.2008.02396.xfr

Fichiers

Bundle original
Voici les éléments 1 - 1 sur 1
Pas de vignette d'image disponible
Nom :
Ruchat_2008.pdf
Taille :
153.8 KB
Format :
Adobe Portable Document Format